摘要
目的探讨含亮氨酸重复序列G-蛋白偶联受体5(1eucine-rich repeat-containing G protein coupled receptor 5,Lgr5)及CD44在卵巢癌中的表达及其与预后的关系。方法选取2006年5月至2010年1月住院并接受手术治疗的卵巢癌患者140例,选取同期本院因卵巢良性病变行肿物剥除或附件切除的40例患者作为对照,应用免疫组化(S-P)方法检测140例卵巢癌组织(卵巢癌组)、140例卵巢癌癌旁组织(癌旁组)、正常卵巢组织40例(正常组)中的Lgr5及CD44蛋白表达,分析其与卵巢癌患者临床病理指标的关系。结果 (1)Lgr5在正常卵巢组织、癌旁组织和卵巢癌中的阳性率分别为5.0%、18.3%和95.7%,差异具有统计学意义(F=24.581,P=0.001);CD44在正常卵巢组织、癌旁组织和卵巢癌中的阳性率分别为7.5%、15.7%和90.0%,差异具有统计学意义(P<0.05)。(2)Lgr5表达与肿瘤分化程度、淋巴结转移及TNM分期有关(P<0.05)。CD44表达与肿瘤分化程度、浸润深度、淋巴结转移及TNM分期有关(P<0.05)。(3)Lgr5及CD44存在正相关性(r=0.3,P<0.05)。(4)Lgr5高表达者(+++)和低表达者(+)^(++)5年总生存率分别为29.2%和51.2%(HR=11.637,95%CI:4.351~18.439;P=0.002);CD44高表达者(+++)和低表达者(+)^(++)5年总生存率分别为35.3%和41.3%(HR=10.142,95%CI:4.285~17.013;P=0.006)。结论 Lgr5及CD44的增强表达与卵巢癌侵袭性增强有密切关系,其表达可作为判断卵巢癌患者预后的指标。
Objective To explore the value of LGR5 and CD44 expression in clinical prognosis analysis of cervical carcinoma. Methods Immunohistochemistry staining method was performed in 140 patients with cervical carcinoma and 40 patients with benign cervical tumor from May 2006 to January 2010 in our hospital. LGR5 and CD44 in the cervical carcinoma tissues （cervical carcinoma group, 140 cases）, para-carcinoma tissues （para-carcinoma group, 140 cases） and normal cervical tissues （normal group, 40 cases） were detected with immunohistochemica1 method. the correlation with clinicopathological parameters of cervical carcinoma were also analyzed. Results （1） There was a significant difference of positive expression rate of Lgr5 among control group, surrounding tissue and cervical carcinoma （5.0% vs 18.3% vs 95.7%） （P〈0.05）. There was also a significant difference of positive expression rate of CD44 among control group, surrounding tissue and cervical carcinoma（7.5% vs 15.7% vs 90.0%）（F=11.538, P=0.001）.（2） The expression of Lgr5 was related with stage, the degree of tumor differentiation, lymph node metastasis and TNM （P〈0.05）. The expression of CD44 had relationship with stage, the degree of tumor differentiation, depth of invasion, lymph node metastasis and TNM （P〈0.05）. There was a positive correlation between LGR5 and CD44 （r=0.3,P〈0.05）. The five-year overall survival （OS） rates for patients with high LGR5 expression （＋＋＋） and low expression （＋）～（＋＋） were 29.2% and 51.2%（HR： 11.637,95%CI： 4.351～18.439, P=0.002）. The five-year overall survival （OS） rates for patients with high CD44 expression （＋＋＋） and low expression （＋）～（＋＋） were 35.3%and 41.3% （HR： 10.142, 95%CI： 4.285～17.013, P=0.006）.Conclusions The up-regulated expression levels of LGR5 and CD44 are closely related to the increased malignancy and invasion of tumors. The expression of protein might act as an indicator the prognosis of
出处
《标记免疫分析与临床》
CAS
2017年第10期1175-1179,1186,共6页
Labeled Immunoassays and Clinical Medicine
